


Credentialed Pharmacist: OPTMED-D Trial Overview



Study enquiries: OPTMED-D@uq.edu.au

What do I (as the credentialed pharmacist) have to do to benefit my patients?

Engagement with credentialed pharmacists

- Credentialed pharmacists servicing Gold Coast and Metro South Brisbane are invited to participate in OPTMED-D study.
- Credentialed pharmacists that agree to participate in OPTMED-D will be offered to complete the new Transition of Care Training Module by PSA (eligible for CPD).
- At the end of our study, we will be asking credentialed pharmacists to complete our post-trial survey/interview.

Step 1: Prior to discharge and at discharge (hospital-based process)

No credentialed pharmacist action required at this stage

- Hospital Pharmacist Navigator stratifies patients based on moderate or high risk post-discharge medication-related harm.
 - Pathway 1 (Moderate risk): The navigator books a post-discharge MedsCheck at the patient's preferred community pharmacy.
 - Pathway 2 (High risk): The navigator contacts the patient's GP to coordinate a post-discharge consultation and referral for Home Medicines Review (HMR). The navigator sends a letter to the GP with discharge medication list via Secure Web Transfer.
- The patients' Discharge Medication Record (DMR) is uploaded to the patient's My Health Record. A physical copy is also provided to the patient.
- In addition to the Electronic Discharge Summary, the GP gets a copy of the DMR via ieMR (Gold Coast Health) or SWT (Metro South Health) and whether the patient is allocated to Pathway 1 or Pathway 2.

Step 2: Post-discharge

Credentialed pharmacist actions (high-risk only):

- The credentialed pharmacist receives GP referral and conducts the post-discharge HMR for high-risk patients.
- The credentialed pharmacist records the activity in the pharmacy log (see next page for hard copy or online form here: <https://bit.ly/optmed-d-log>)
- Credentialed pharmacist sends the HMR report to the GP and discusses the results with the GP.

Contact

OPTMED-D Study Email: OPTMED-D@uq.edu.au

Principal Investigator: Laetitia Hattingh (laetitia.hattingh@health.qld.gov.au)